BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Idarubicin

An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.

299+ PubMed studies analyzed · 19 RCTs · Evidence Score: 48.6

Research Domains

Idarubicin has been studied across 12 research domains including 🔬 Oncology, 😴 Sleep, 🫁 Liver & Detox, ⏳ Longevity & Aging, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 41% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Idarubicin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Daunorubicin
29 shared targets
Aurintricarboxylic
22 shared targets
Benzethonium
16 shared targets
oxatomide
16 shared targets
triolimus
13 shared targets
piceatannol
19 shared targets
Dequalinium
14 shared targets
ag490
11 shared targets
Nitroprusside
8 shared targets
Emetine
15 shared targets
Loading evidence profile...

This evidence profile for Idarubicin is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.